- Home
- / Menlo Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Menlo Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2.7
2024-10-29
Market Capitalization
$39.7 M
2024-10-29
Revenue
$570 K
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | Y, 2017 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.0M | 21.0M | 14.8M | 477.0K | 400.0K | 500.0K | 570.0K | |||
| Cost of goods sold | 1.4M | 3.3M | ||||||||
| Gross profit | 19.6M | 11.4M | ||||||||
| Gross profit margin, % | 93.4% | 77.3% | ||||||||
| General and administrative expense | 5.2M | 12.2M | 22.5M | 89.5M | 54.5M | 16.4M | 13.4M | 13.2M | 11.1M | |
| Operating expense total | 34.2M | 65.2M | 76.2M | 272.1M | 79.4M | 34.8M | 44.1M | 30.3M | ||
| Depreciation and amortization | 23.0K | |||||||||
| EBIT | (29.6M) | (54.5M) | (76.2M) | (252.5M) | (68.0M) | (34.3M) | (29.3M) | (43.6M) | (29.7M) | |
| EBIT margin, % | -1203.0% | -461.1% | -7189.7% | -8727.4% | -5219.1% | |||||
| Interest expense | 517.0K | 4.4M | 5.6M | |||||||
| Pre tax profit | (255.8M) | (73.8M) | (33.9M) | (27.9M) | (39.8M) | (26.7M) | ||||
| Income tax expense | (258.0K) | (448.0K) | 13.0K | 4.0K | 4.0K | |||||
| Net Income | (29.1M) | (51.4M) | (73.7M) | (255.6M) | (73.3M) | (23.2M) | (28.5M) | (39.8M) | (26.5M) | |
| EPS | 1.4 | (7.3) | (2.0) | (0.9) | (0.6) |